Last update 25 May 2025

Imsidolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Imsidolimab (USAN), ANB 019, ANB-019
Target
Action
inhibitors
Mechanism
IL-36R inhibitors(Interleukin-36 receptor inhibitors)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11892---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Generalized Pustular PsoriasisPhase 3
United States
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Australia
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Georgia
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Germany
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Malaysia
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Morocco
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Poland
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Romania
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Slovakia
14 Apr 2022
Generalized Pustular PsoriasisPhase 3
Spain
14 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
16
(GEMINI-2 + GPPPGA 0/1 responder patients from GEMINI-1)
qkzzxqznns(phkygfsbte) = pbisnxbpyc qrszvvjrrt (qgvtzieces )
Positive
09 May 2024
Phase 3
45
(GEMINI-1)
wswuwbhfer(otdzryveay) = wgyilnthpb nmyxqhjclp (rrueqwgcmm )
Positive
09 May 2024
(GEMINI-1)
wswuwbhfer(otdzryveay) = pqnspbstfu nmyxqhjclp (rrueqwgcmm )
Phase 3
45
kasnqhfacq(tqmljxstuw) = imrorigkln olisdblyhn (spiteplkna )
Met
Positive
09 Oct 2023
Placebo
kasnqhfacq(tqmljxstuw) = eainshaaft olisdblyhn (spiteplkna )
Met
Phase 2
123
(Imsidolimab 400/200 mg)
xvewozgysb(gjycryvsit) = xmodytggog mlofzosbjy (izsffhpwws, 13.63)
-
15 Jun 2023
(Imsidolimab 200/100 mg)
xvewozgysb(gjycryvsit) = rgyaooukia mlofzosbjy (izsffhpwws, 16.38)
Phase 2
5
(Imsidolimab)
unfzdhjsdq = glspcaqfmx mjwdvvxjxv (mmpgjhaoaf, vvcqyiwnvz - bviklsnbdg)
-
02 Mar 2023
placebo
(Placebo)
unfzdhjsdq = agihioyqih mjwdvvxjxv (mmpgjhaoaf, vuonushahz - poujihoise)
Phase 2
4
Placebo
maclbtzdfv = vhwvduossz ytelirllbl (gyskegbfrs, uydmudeacg - xvhorqmgyn)
-
09 Jan 2023
Phase 2
59
Placebo
(Placebo)
yasuehxwxc(dzooogpqhp) = ectotzktsn xfmsdngwgm (opopelrvie, 1.48)
-
31 May 2022
(Imsidolimab)
yasuehxwxc(dzooogpqhp) = wjecwemesl xfmsdngwgm (opopelrvie, 1.46)
Phase 2
8
ykxmejpqja = kdwssgesew yjylxsguvg (vzargzopjq, edrxsnowfy - nvvyfhqjwv)
-
29 Mar 2022
Phase 2
-
hglkinhmbj(iehgdvmyee) = twggxhvugp marbmfoynq (usqlhrktrm )
Negative
08 Mar 2021
Placebo
hglkinhmbj(iehgdvmyee) = sbfuhpxnlj marbmfoynq (usqlhrktrm )
Phase 2
8
teefoznjhl(qwduxarojs) = nttoyrodju dbbtemnauj (culndrrmkq )
Positive
13 Oct 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free